Large Insider Purchases
Institutional-Scale SEC Form 4 Buy Signals
The Signal of $1M+ Conviction
When a corporate executive invests more than $1,000,000 of their own capital into company shares, it represents the highest level of conviction. These seven-figure purchases reflect management's belief in the company's future value.
| Filing Date | Trade Date | Ticker | Company Name | Reporting Person | Relationship | Industry | Type | Price | Qty | Total, $ | Owned After | Change, % |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-02-23 00:59 | 2024-02-21 | BCAT | BlackRock Capital Allocation Term Trust | Saba Capital Management, L.P. | 10% owner | Other | BUY | $15.51 | 129,047 | $2,001,248 | 15,005,664 | +0.9% |
| 2024-02-23 04:06 | 2024-02-20 | CART | Maplebear Inc. | SC US (TTGP), LTD. | 10% owner | Services-Business Services, NEC | BUY | $28.54 | 2,020,273 | $57,655,763 | 2,012,859 | +100.0% |
| 2024-02-23 00:43 | 2024-02-20 | FCNCA | FIRST CITIZENS BANCSHARES INC /DE/ | BRYANT HOPE HOLDING | Director, Officer, 10% owner - Vice Chairwoman | State Commercial Banks | BUY | $1,314.97 | 766 | $1,007,267 | 1,978 | +63.2% |
| 2024-02-21 20:54 | 2024-02-16 | ECAT | BlackRock ESG Capital Allocation Term Trust | Saba Capital Management, L.P. | 10% owner | Other | BUY | $16.67 | 116,778 | $1,946,549 | 26,593,897 | +0.4% |
| 2024-02-21 20:51 | 2024-02-16 | BMEZ | BlackRock Health Sciences Term Trust | Saba Capital Management, L.P. | 10% owner | Other | BUY | $15.91 | 267,863 | $4,260,656 | 19,578,308 | +1.4% |
| 2024-02-21 20:48 | 2024-02-16 | BIGZ | BlackRock Technology & Private Equity Term Trust | Saba Capital Management, L.P. | 10% owner | Other | BUY | $8.02 | 219,816 | $1,763,276 | 49,210,459 | +0.4% |
| 2024-02-21 20:46 | 2024-02-16 | BCAT | BlackRock Capital Allocation Term Trust | Saba Capital Management, L.P. | 10% owner | Other | BUY | $15.50 | 234,991 | $3,641,444 | 14,876,617 | +1.6% |
| 2024-02-21 01:38 | 2024-02-15 | PRME | Prime Medicine, Inc. | ARCH Venture Partners XII, LLC | 10% owner | Biological Products, (No Diagnostic Substances) | BUY | $6.25 | 3,200,000 | $20,000,000 | 3,200,000 | +100.0% |
| 2024-02-20 19:27 | 2024-02-15 | N/A | N/A | UAW Chrysler Retirees Medical Benefits Plan | 10% owner | Other | BUY | $5,308.00 | 4,663 | $24,749,999 | 20,296 | +29.8% |
| 2024-02-21 02:03 | 2024-02-16 | CRMT | AMERICAS CARMART INC | Peterson Adam K | 10% owner | Retail-Auto Dealers & Gasoline Stations | BUY | $61.60 | 23,105 | $1,423,229 | 696,305 | +3.4% |
| 2024-02-20 14:30 | 2024-02-16 | ADC | Agree Realty Corporation | RAKOLTA JOHN JR | Director | Real Estate Investment Trusts | BUY | $57.00 | 20,430 | $1,164,510 | 392,549 | +5.5% |
| 2024-02-21 00:11 | 2024-02-20 | IOVA | IOVANCE BIOTHERAPEUTICS, INC. | Rothbaum Wayne P. | Director | Biological Products, (No Diagnostic Substances) | BUY | $9.15 | 5,000,000 | $45,750,000 | 28,067,333 | +21.7% |
| 2024-02-21 01:00 | 2024-02-15 | MNKTQ | N/A | GOLDENTREE ASSET MANAGEMENT LP | 10% owner | Other | BUY | $38.25 | 225,000 | $8,606,250 | 2,316,035 | +10.8% |
| 2024-02-21 00:57 | 2024-02-16 | GTES | Gates Industrial Corp plc | SIMPKINS NEIL P | Director | General Industrial Machinery & Equipment | BUY | $12.20 | 1,000,000 | $12,200,000 | 1,000,000 | +100.0% |
| 2024-02-21 01:41 | 2024-02-15 | PRME | Prime Medicine, Inc. | NELSEN ROBERT | Director, 10% owner | Biological Products, (No Diagnostic Substances) | BUY | $6.25 | 3,200,000 | $20,000,000 | 3,200,000 | +100.0% |
| 2024-02-21 01:37 | 2024-02-15 | PRME | Prime Medicine, Inc. | ARCH Venture Partners X, LLC | 10% owner | Biological Products, (No Diagnostic Substances) | BUY | $6.25 | 3,200,000 | $20,000,000 | 3,200,000 | +100.0% |
| 2024-02-21 03:52 | 2024-02-20 | IOVA | IOVANCE BIOTHERAPEUTICS, INC. | MCPEAK MERRILL A | Director | Biological Products, (No Diagnostic Substances) | BUY | $9.15 | 250,000 | $2,287,500 | 320,150 | +356.4% |
| 2024-02-17 01:35 | 2024-02-14 | SOC | Sable Offshore Corp. | Flores James Caldwell | Officer - President | Crude Petroleum & Natural Gas | BUY | $10.00 | 300,000 | $3,000,000 | 371,875 | +417.4% |
| 2024-02-17 00:57 | 2024-02-12 | SOC | Sable Offshore Corp. | FLORES JAMES C | Director, Officer, 10% owner - Chairman & CEO | Crude Petroleum & Natural Gas | BUY | $10.01 | 3,217,500 | $32,200,097 | 2,525,000 | +100.0% |
| 2024-02-16 23:01 | 2024-02-14 | AREN | Arena Group Holdings Inc. | Simplify Inventions, LLC | 10% owner | Cable & Other Pay Television Services | BUY | $2.16 | 5,555,555 | $11,999,999 | 16,067,791 | +52.8% |
| 2024-02-17 01:13 | 2024-02-15 | AYX | N/A | Stoecker Dean | Director, 10% owner | Other | BUY | $47.90 | 42,500 | $2,035,750 | 77,500 | +121.4% |
| 2024-02-17 01:17 | 2024-02-14 | SOC | Sable Offshore Corp. | Sarofim Christopher Binyon | Director, 10% owner | Crude Petroleum & Natural Gas | BUY | $10.00 | 6,000,000 | $60,000,000 | 3,000,000 | +100.0% |
| 2024-02-17 00:10 | 2020-04-01 | TELA | TELA Bio, Inc. | EW HEALTHCARE PARTNERS FUND 2, L.P. | 10% owner, Other | Surgical & Medical Instruments & Apparatus | BUY | $9.32 | 326,062 | $3,038,311 | 3,610,709 | +9.9% |
| 2024-02-17 00:48 | 2024-02-14 | EMKR | N/A | Archon Capital Management LLC | 10% owner | Other | BUY | $0.36 | 4,851,568 | $1,748,020 | 12,552,577 | +63.0% |
| 2024-02-17 03:57 | 2024-02-14 | SOC | Sable Offshore Corp. | Pipkin Gregory Phillip | Director | Crude Petroleum & Natural Gas | BUY | $10.00 | 100,000 | $1,000,000 | 196,875 | +103.2% |
| 2024-02-16 22:37 | 2024-02-16 | LRMR | Larimar Therapeutics, Inc. | Flynn James E | Director, 10% owner, Other | Pharmaceutical Preparations | BUY | $8.74 | 4,290,617 | $37,499,993 | 4,207,982 | +100.0% |
| 2024-02-16 01:05 | 2024-02-13 | ECAT | BlackRock ESG Capital Allocation Term Trust | Saba Capital Management, L.P. | 10% owner | Other | BUY | $16.72 | 285,038 | $4,765,693 | 26,477,119 | +1.1% |
| 2024-02-16 01:02 | 2024-02-13 | BMEZ | BlackRock Health Sciences Term Trust | Saba Capital Management, L.P. | 10% owner | Other | BUY | $15.84 | 162,282 | $2,570,920 | 19,310,445 | +0.8% |
| 2024-02-16 00:59 | 2024-02-13 | BIGZ | BlackRock Technology & Private Equity Term Trust | Saba Capital Management, L.P. | 10% owner | Other | BUY | $8.05 | 799,196 | $6,430,731 | 48,990,643 | +1.7% |
| 2024-02-16 00:55 | 2024-02-13 | BCAT | BlackRock Capital Allocation Term Trust | Saba Capital Management, L.P. | 10% owner | Other | BUY | $15.54 | 163,586 | $2,541,456 | 14,641,626 | +1.1% |
| 2024-02-16 04:38 | 2024-02-09 | MGX | Metagenomi Therapeutics, Inc. | Novo Holdings A/S | 10% owner | Biological Products, (No Diagnostic Substances) | BUY | $14.47 | 900,000 | $13,024,980 | 1,739,175 | +107.2% |
| 2024-02-15 23:57 | 2024-02-13 | PLCE | Childrens Place, Inc. | Mithaq Capital SPC | 10% owner | Retail-Family Clothing Stores | BUY | $11.15 | 966,344 | $10,778,988 | 6,751,387 | +16.7% |
| 2024-02-14 17:18 | 2024-02-13 | WT | WisdomTree, Inc. | Steinberg Jonathan L | Director, Officer - Chief Executive Officer | Security Brokers, Dealers & Flotation Companies | BUY | $7.20 | 303,781 | $2,186,768 | 9,172,838 | +3.4% |
| 2024-02-15 02:53 | 2024-02-13 | FORFX | N/A | Peters Raleigh | Director | Other | BUY | $9.54 | 200,000 | $1,908,000 | 20,964 | +100.0% |
| 2024-02-15 00:15 | 2024-02-13 | COOP | N/A | Weinbach Michael S | Officer - President | Other | BUY | $71.16 | 17,000 | $1,209,720 | 17,000 | +100.0% |
| 2024-02-15 03:04 | 2024-02-12 | KYTX | Kyverna Therapeutics, Inc. | Vida Ventures, LLC | 10% owner | Biological Products, (No Diagnostic Substances) | BUY | $22.00 | 253,136 | $5,568,992 | 583 | +100.0% |
| 2024-02-15 01:26 | 2024-02-12 | KYTX | Kyverna Therapeutics, Inc. | Bain Capital Life Sciences Investors, LLC | 10% owner | Biological Products, (No Diagnostic Substances) | BUY | $22.00 | 450,000 | $9,900,000 | 3,163,868 | +16.6% |
| 2024-02-15 05:06 | 2024-02-12 | MLYS | Mineralys Therapeutics, Inc. | Samsara BioCapital GP, LLC | 10% owner | Pharmaceutical Preparations | BUY | $13.50 | 555,555 | $7,499,993 | 5,074,916 | +12.3% |
| 2024-02-15 00:15 | 2024-02-12 | TNYA | Tenaya Therapeutics, Inc. | COLUMN GROUP III GP, LP | 10% owner | Biological Products, (No Diagnostic Substances) | BUY | $4.50 | 2,222,222 | $9,999,999 | 13,599,275 | +19.5% |
| 2024-02-15 00:12 | 2024-02-12 | TNYA | Tenaya Therapeutics, Inc. | GOEDDEL DAVID V | Director, 10% owner | Biological Products, (No Diagnostic Substances) | BUY | $4.50 | 2,222,222 | $9,999,999 | 13,599,275 | +19.5% |
| 2024-02-15 03:51 | 2024-02-12 | PLCE | Childrens Place, Inc. | Mithaq Capital SPC | 10% owner | Retail-Family Clothing Stores | BUY | $15.80 | 1,566,475 | $24,749,522 | 4,663,743 | +50.6% |
| 2024-02-14 01:48 | 2024-02-12 | KYTX | Kyverna Therapeutics, Inc. | GILEAD SCIENCES, INC. | 10% owner | Biological Products, (No Diagnostic Substances) | BUY | $22.00 | 910,000 | $20,020,000 | 4,126,119 | +28.3% |
| 2024-02-14 03:22 | 2024-02-01 | AYX | N/A | Stoecker Dean | Director, 10% owner | Other | BUY | $47.46 | 35,000 | $1,661,100 | 60,000 | +140.0% |
| 2024-02-14 03:48 | 2024-02-13 | HLXB | BridgeBio Oncology Therapeutics, Inc. | Chen Bihua | Director, Officer, 10% owner - CEO and Chairperson | Pharmaceutical Preparations | BUY | $10.00 | 2,400,000 | $24,000,000 | 903,600 | +100.0% |
| 2024-02-14 00:33 | 2024-02-09 | PEPG | PepGen Inc. | RA CAPITAL MANAGEMENT, L.P. | Director, 10% owner | Pharmaceutical Preparations | BUY | $10.64 | 2,557,593 | $27,212,790 | 9,179,273 | +38.6% |
| 2024-02-14 00:05 | 2024-02-09 | MRCY | MERCURY SYSTEMS INC | JANA Partners Management, LP | Director, 10% owner, Other | Electronic Components & Accessories | BUY | $27.90 | 1,335,848 | $37,270,159 | 6,553,120 | +25.6% |
| 2024-02-14 05:11 | 2024-02-09 | PLCE | Childrens Place, Inc. | Mithaq Capital SPC | 10% owner | Retail-Family Clothing Stores | BUY | $11.02 | 1,849,397 | $20,387,198 | 3,097,268 | +148.2% |
| 2024-02-13 00:58 | 2024-02-08 | NANX | SOLESENCE, INC. | WHITMORE BRADFORD T | 10% owner | Perfumes, Cosmetics & Other Toilet Preparations | BUY | $0.40 | 3,824,864 | $1,529,946 | 57,791 | +100.0% |
| 2024-02-13 01:51 | 2024-02-12 | KYTX | Kyverna Therapeutics, Inc. | Northpond Ventures III GP, LLC | Other | Biological Products, (No Diagnostic Substances) | BUY | $22.00 | 450,000 | $9,900,000 | 450,000 | +100.0% |
| 2024-02-13 01:43 | 2024-02-08 | SANA | Sana Biotechnology, Inc. | ARCH Venture Fund X, L.P. | 10% owner | Biological Products, (No Diagnostic Substances) | BUY | $5.50 | 1,818,181 | $9,999,996 | 12,446,022 | +17.1% |
Institutional Conviction in Form 4
Tracking these institutional-scale purchases allows you to follow the "smart money" when their conviction is highest. When an executive or a 10% beneficial owner commits a seven-figure sum to an open-market transaction, it bypasses the routine noise of stock-based compensation. These trades are often a precursor to major corporate developments or a signal that management views the current market valuation as significantly disconnected from the company’s internal growth trajectory. By monitoring these high-value entries, investors can align their portfolios with the capital of those who possess the most intimate understanding of a business's long-term health and potential.
Filtering the Market Noise
Our platform is designed to eliminate the noise and focus strictly on high-impact accumulation from directors and CEOs betting big on their company’s future. The SEC EDGAR database is frequently flooded with thousands of automated Form 4 filings, many of which involve small, technical, or pre-scheduled trades that offer little predictive value for the average investor. By applying a strict $1,000,000 minimum threshold, we isolate the transactions where insiders are taking substantial personal financial risk. This high-conviction filter serves as a powerful transparency tool, identifying the exact moments when corporate leadership moves away from passive ownership toward aggressive capital deployment.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.